Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia

At the initiation of induction for non-intubated general anesthesia, ciprofol or propofol will be administered intravenously at a rate of 10 mL/min. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to evaluate sedation depth. This study aims to assess the effects of ciprofol and propofol on hemodynamics and respiratory function in elderly patients undergoing non-intubated general anesthesia.

Panoramica dello studio

Descrizione dettagliata

Inclusion Criteria

  1. Patients scheduled for elective non-intubated general anesthesia
  2. Age ranging from 65 to 80 years old
  3. American Society of Anesthesiologists (ASA) physical status class I-III
  4. Written informed consent signed by the patient or legal guardian

Exclusion Criteria

  1. Confirmed allergy to propofol, ciprofol or their excipients
  2. Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
  3. Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
  4. Severe hepatic or renal insufficiency
  5. Long-term regular use of sedatives or opioids
  6. Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria

1. Patients with allergic reactions to study drugs or other severe complications during the trial

2. Severe hypoxemia requiring emergency endotracheal intubation

3. Severe hemodynamic instability occurring during induction

4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).

Observation Indicators

Baseline Demographic Data

Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.

Primary Observation Indicators

Hemodynamic parameters (Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR)) and respiratory parameters (peripheral oxygen saturation (SpO₂), respiratory rate (RR), end-tidal carbon dioxide (EtCO₂)) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.

Secondary Observation Indicators

  1. Baseline BIS value and minimum BIS value during induction
  2. Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
  3. Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.

Anesthetic Protocol

All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.

Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.

Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.

Rescue Management Protocols

  • Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
  • Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
  • Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
  • Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
  • Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.

Tipo di studio

Interventistico

Iscrizione (Stimato)

108

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Ningxia
      • Yinchuan, Ningxia, Cina, 750000
        • Reclutamento
        • Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Patients scheduled for elective non-intubated general anesthesia
  2. Age ranging from 65 to 80 years old
  3. American Society of Anesthesiologists (ASA) physical status class I-III
  4. Written informed consent signed by the patient or legal guardian

Exclusion Criteria:

  1. Confirmed allergy to propofol, ciprofol or their excipients
  2. Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
  3. Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
  4. Severe hepatic or renal insufficiency
  5. Long-term regular use of sedatives or opioids
  6. Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia. The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min. The administration will cease when the MOAA/S score is ≤1. Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction. The safety of the medication will be evaluated in comparison with the control group
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
Comparatore attivo: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point. Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction. This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point. This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Lasso di tempo: 5 minutes after induction of anesthesia
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients. Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia. Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions. Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation, respiratory rate , end-tidal carbon dioxid within the 5-minute induction period. A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
5 minutes after induction of anesthesia

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Brain electrical activity sedation depth (BIS)
Lasso di tempo: 5 minutes after induction of anesthesia
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
5 minutes after induction of anesthesia
incidence of induction period circulatory/respiratory adverse events
Lasso di tempo: 5 minutes after induction of anesthesia
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
5 minutes after induction of anesthesia

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 luglio 2026

Completamento primario (Stimato)

1 febbraio 2027

Completamento dello studio (Stimato)

1 aprile 2027

Date di iscrizione allo studio

Primo inviato

22 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

22 giugno 2026

Primo Inserito (Effettivo)

26 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 agosto 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi